Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Narrative review explores Vaccinia virus therapy for non-small cell lung cancer with noted delivery challenges
Vaccinia Virus May Turn Cold Lung Tumors Into Hot Targets For Immune Attack
This narrative review examines preclinical and early clinical data regarding Vaccinia virus therapy for non-small cell lung cancer. The auth…
A repurposed virus from smallpox vaccines might finally help the immune system attack lung cancer tumors that have stopped responding to sta…
FDA Approves Lazcluze (lazertinib) with Amivantamab for EGFR-Mutant NSCLC
FDA approves new lung cancer pill Lazcluze for certain patients.
FDA approved Lazcluze (lazertinib) in combination with amivantamab for first-line treatment of adults with locally advanced or metastatic NS…
The FDA approved Lazcluze (lazertinib) with another drug for adults with a common type of advanced lung cancer. This new oral treatment is f…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
A Hidden Protein Switch May Fuel Cancer Growth and Drug Resistance
This narrative review addresses multiple malignancies including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pa…
A single protein called PRMT3 helps multiple cancers grow, hide from the immune system, and resist chemotherapy, making it a promising new t…
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
A systematic review and meta-analysis of real-world studies evaluated first-line pembrolizumab monotherapy for advanced NSCLC with high PD-L…
New data from thousands of patients shows pembrolizumab provides reliable long-term survival for advanced lung cancer without major safety s…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Combination therapy shows promising progression-free survival in advanced non-small cell lung cancer patients with high PD-L1 expression
Early trial shows two-drug combo may help advanced lung cancer patients
This randomized phase 2 trial evaluated domvanalimab plus zimberelimab compared to zimberelimab alone or chemotherapy in patients with advan…
A Phase 2 trial suggests a two-drug combination might improve outcomes for some patients with advanced lung cancer compared to standard chem…
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
Phase I trial shows subcutaneous tislelizumab reaches high drug levels in lung cancer patients
This phase I trial evaluated subcutaneous versus intravenous tislelizumab in treatment-naive patients with advanced non-small cell lung canc…
Early data suggest subcutaneous tislelizumab injections may offer similar drug levels to intravenous forms for treating advanced lung cancer…
RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial
New drug shows promise for KRASG12D lung and pancreatic cancers
This phase Ia trial evaluated RNK08954 in 36 patients with KRASG12D-mutant non-small cell lung cancer or pancreatic ductal adenocarcinoma.
An early trial of RNK08954 shrank tumors in 58% of lung cancer patients with a specific KRAS mutation.
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical
Gut Health Links May Influence Lung Cancer Treatment Paths
This narrative review with a systematic search examined 168 studies on the gut-lung axis in non-small-cell and small-cell lung cancer. Solub…
New research explores how the gut-lung axis and specific metabolites might play a role in managing lung cancer treatments.
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
New Treatment Approach Shows Success for a Rare Type of Lung Cancer
This case report describes a 61-year-old man with high-grade thoracic malignancy who achieved a pathologic complete response and undetectabl…
A 61-year-old man with a rare lung cancer showed a complete response after receiving a specific mix of drugs and surgery.
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
Understanding the Role of PGE2 Signaling in Brain Health and Cancer
This systematic review examines the role of PGE2 signaling across neurological, oncological, and metabolic conditions. The findings indicate…
New research shows how different parts of a single protein pathway can either protect your brain or help tumors grow.
Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers
Protein D shows promise in diagnosing and treating several cancers
This narrative review explores the role of Surfactant protein D (SP-D) across multiple malignancies, including lung adenocarcinoma and breas…
A specific protein called Surfactant protein D may help doctors identify lung cancer and fight cells in breast and leukemia cases.
B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer
B7-H3 Targeted Drugs Show Promise for Small Cell Lung Cancer
This systematic review and meta-analysis evaluates B7-H3-targeted antibody-drug conjugates for patients with previously treated small cell l…
New data suggests B7-H3 targeted therapies may offer higher response rates than standard treatments for patients with small cell lung cancer…
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
This meta-analysis of 3,910 patients with extensive-stage small-cell lung cancer (ES-SCLC) found that first-line immune checkpoint inhibitor…
Combining immune checkpoint inhibitors with chemotherapy shows better survival rates for patients with extensive stage small cell lung cance…
Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura
New Case Highlights Rare Kidney Risk in Lung Cancer Treatment
This case report and literature review describes a patient with stage IVB lung adenocarcinoma who developed iTTP after receiving an ivonesci…
A single case report identifies a rare blood and kidney condition that can occur during specific lung cancer treatments involving ivonescima…
Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
Combined Treatments May Help Manage Brain Metastases in Lung Cancer
This case report and literature review describes a patient with EGFR-mutant NSCLC and brain/leptomeningeal metastases. The authors suggest t…
A new treatment approach combining surgery, local chemotherapy, and targeted drugs may help manage brain cancer spread for some patients.
Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
Immunotherapy Combined With Chemoradiotherapy Shows Promise for Lung Cancer
This meta-analysis of randomized controlled trials evaluated the impact of chemoradiotherapy (CCRT) plus immunotherapy on 1,853 patients wit…
Adding immunotherapy to standard chemoradiotherapy shows a favorable trend in survival for patients with limited-stage small-cell lung cance…
Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
Lung cancer can change form after targeted drug treatment
A case report with literature review describes a 71-year-old man with KRAS G12C-mutant lung adenocarcinoma whose tumor transformed to pulmon…
A man's lung cancer transformed into a more aggressive type after taking the targeted drug sotorasib, highlighting the need for re-biopsy wh…
CT-based deep learning models show high accuracy predicting EGFR mutation status in lung adenocarcinoma
Machine learning models help predict lung cancer mutations from scans
This meta-analysis of 6,628 Chinese patients with lung adenocarcinoma found that machine learning-based radiomics models provide a noninvasi…
New analysis shows that deep learning models can accurately identify specific lung cancer mutations using standard CT scans.
Questions about Non-Small Cell Lung Cancer
Can morning timing of immune checkpoint infusions improve survival outcomes in metastatic non-small cell lung cancer patients?
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear benefits.
Full answer →Does a phase III trial show sublobar resection is better than lobectomy for small peripheral non–small cell lung cancer?
Yes, a phase III trial (CALGB 140503) found sublobar resection noninferior to lobectomy for disease-free survival in small peripheral NSCLC ≤2 cm.
Full answer →How do bispecific antibodies and CAR T-cell therapy work for advanced non–small cell lung cancer?
Bispecific antibodies and CAR T-cell therapy are two immunotherapies being tested for advanced NSCLC; bispecific antibodies show more clinical progress, while CAR T faces challenges like toxicity and tumor trafficking.
Full answer →What does the research say about using chemotherapy versus immunotherapy for advanced Non-Small Cell Lung Cancer?
For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Full answer →How does high PD-L1 expression affect treatment choices for advanced Non-Small Cell Lung Cancer?
High PD-L1 expression (≥50%) often makes immunotherapy, such as pembrolizumab, a first-line option for advanced NSCLC, but other factors like mutations also guide treatment.
Full answer →Can you explain the global disparities in access to new therapies for advanced Non-Small Cell Lung Cancer?
Global disparities in access to new NSCLC therapies stem from differences in drug approval, cost, testing infrastructure, and healthcare system resources.
Full answer →Is camrelizumab associated with a higher risk of disease progression compared to pembrolizumab?
In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one real-world study.
Full answer →Does real-world data support using pembrolizumab for my advanced Non-Small Cell Lung Cancer?
Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of 21 months and 29% survival at 5 years.
Full answer →